Medical/Pharmaceuticals

Antengene to Present Latest Preclinical Results of Novel Cos-TCE Platform in Rapid Oral Abstract Presentation at SITC 2026

SHANGHAI and HONG KONG, Oct. 3, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dise...

2026-10-03 08:30 10841

/DISREGARD RELEASE: Jiangsu Vcare/

We are advised by Jiangsu Vcare that journalists and other readers should disregard the news release, Jiangsu Vcare Files NDA for Vicagrel Capsules with US FDA, issued 04-Jan-2024 over PR Newswire. ...

2026-10-02 19:12 5196

Chiron Medical Group's October "Safeguarding Breast Health With Heart" Campaign: Integrating Breast Health into Daily Life

"Safeguarding Breast Health With Heart" HONG KONG, Oct. 2, 2026 /PRNewswire/ -- As we enter Breast Cancer Awareness Month in October, Chiron Medical Group, together with its FemWell Women's Health Centre and Chiron Breast Health Centre, is launching a series of activities under the theme "Safegu...

2026-10-02 17:48 2688

Ascletis' ASC36_35FDC Demonstrated Potential for Once-Monthly to Once-Quarterly Dosing and Robust Weight-Loss in Preclinical Studies Presented at EASD 2026

HONG KONG, Oct. 2, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announced the presentation of key preclinical data for its ASC36_35FDC (ASC36_35 co-formulation) at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting, being held September 28–Oc...

2026-10-02 17:00 4312

Lundbeck to showcase progress across its movement disorders pipeline with data in multiple system atrophy and Parkinson's disease at MDS® 2026

* Late-breaking Phase III MASCOT oral presentation will characterize the clinical profile and diversity of participants in Lundbeck's ongoing global Phase III trial investigating amlenetug in multiple system atrophy (MSA) * New research across clinical trial endpoints, biomarkers, diagnostic t...

2026-10-02 15:05 4398

Abogen Announces Licensing and Option Agreement with Novartis to Advance mRNA-Encoded T-Cell Engager and other potential RNA programs

Includes worldwide license to ABO2203, Abogen's mRNA-encoded CD19xCD3 T-Cell Engager Agreement also gives Novartis exclusive options to license other potential programs leveraging Abogen's RNA proprietary platform SUZHOU, China, Oct. 2, 2026 /PRNewswire/ -- Abogen Biosciences ("Abogen" or the ...

2026-10-02 12:42 3643

I Peace Selected as a TOP 10 Awardee for the "Top 10 Longevity Breakthrough Awards 2026"

PALO ALTO, Calif., Oct. 1, 2026 /PRNewswire/ -- I Peace Inc., a biotech company pioneering induced pluripotent stem cell (iPScell) technologies for regenerative medicine and longevity, today announced that it was selected as one of the awardees for the Top 10 Longevity Breakthrough Awards at the ...

2026-10-02 06:10 2406

ENA Members Choose Vanessa Gorman as 2027 President-elect

Secretary/treasurer, two board members also picked in annual election SCHAUMBURG, Ill., Oct. 2, 2026 /PRNewswire/ -- A believer in the power of connecting people and building the community of emergency and forensic nurses, Vanessa Gorman, DNP, MSN, RN, CCRN, FAEN, FCENA, of Australia, has been ch...

2026-10-02 04:30 2097

A Formidable Type of Childhood Cancer Gets Added to Highly Regarded Library of Treatment Recommendations

New NCCN Guidelines for Pediatric Bone Sarcoma focus on how to provide the best care possible for children and adolescents with Ewing sarcoma. PLYMOUTH MEETING, Pa., Oct. 1, 2026 /PRNewswire/ -- Today, the National Comprehensive Cancer Network® (NCCN®) published the first-ever edition of NCCN Cl...

2026-10-01 21:44 3789

Bambusa Therapeutics Initiates Subcutaneous Dosing of BBT001 in Atopic Dermatitis, Following Compelling Intravenous Proof-of-Concept Data

First patient dosed as Bambusa expands global development of its long-acting bispecific antibody targeting both IL-4Rα and IL-31 High-concentration subcutaneous formulation designed to combine BBT001's emerging profile of rapid, deep and durable clinical activity with convenient administration a...

2026-10-01 21:00 3376

Advances in Digital Therapeutics and HoneyNaps AI Enhance Clinical Trial Efficiency

* Supporting pharmaceutical, medical device, wellness, and research organizations in obtaining standardized sleep data * Expanding the use of SOMNUM scoring technology to provide clinical analysis services tailored to each customer's research objectives * AI Technologies Supporting Global...

2026-10-01 19:00 3065

Emerald Clinical Trials Appoints Michael Stibilj as Chief Executive Officer to Lead Next Phase of Global Growth

SINGAPORE, Oct. 1, 2026 /PRNewswire/ -- Emerald  Clinical Trials

2026-10-01 11:00 5349

Piramal Pharma Solutions and NP2 to Complete Cyclophosphamide Development Phase Next Month

* Piramal and NP2 are set to complete the drug development phase of the generic cancer drug cyclophosphamide this October. * The development and manufacturing activities are being conducted at Piramal's dedicated sterile injectable facility in Lexington, Kentucky. * This partnership addresse...

2026-09-30 21:54 2096

Phrontline Biopharma Doses First Patient in Global Phase I/II Trial of TJ102, an FRα × CDH6 Bispecific Dual-Payload ADC

First clinical program built on Phrontline's DLP1 branched dual-payload linker platform HANGZHOU, China and SHANGHAI, Sept. 30, 2026 /PRNewswire/ -- Phrontline Biopharma, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs), today announced that the f...

2026-09-30 21:53 2743

The 94th CMEF, the World's Leading Medical Device Industry Event, Set to Open in Beijing Oct. 21-24

BEIJING, Sept. 30, 2026 /PRNewswire/ -- The 94th China International Medical Equipment Fair (CMEF) and concurrent events—including ICMD, covering medical device design and manufacturing; CRS, focusing on rehabilitation and assistive technology; CECN, dedicated to elderly care and nursing; and Hea...

2026-09-30 21:16 1974

Yuyu Pharma Brings Ari's Purrfect to Amazon Accelerate 2026

Korean pharmaceutical company explores Amazon AI and seller tools to grow its U.S. feline-health brand SEOUL, South Korea, Sept. 30, 2026 /PRNewswire/ -- Robert Wonsang Yu, CEO of Yuyu Pharma (KRX: 000220), attended Amazon Accelerate 2026 in Seattle from September 22 to 24 to explore how Amazon'...

2026-09-30 21:00 1702

Zhendong Pharmaceutical Announces Publication of Phase IIb Study of Investigational Vaginal Lactobacillus Capsule in the National Medical Journal of China

BEIJING, Sept. 30, 2026 /PRNewswire/ -- Zhendong Pharmaceutical announced that results from a multicenter, randomized, double-blind, placebo-controlled Phase IIb study evaluating its investigational Live Double Combined Lactobacillus Capsule for Vaginal Use for the treatmen...

2026-09-30 20:00 1567

Zhendong Pharmaceutical Announces Publication of Phase IIb Study of Investigational Vaginal Lactobacillus Capsule in the National Medical Journal of China

BEIJING, Sept. 30, 2026 /PRNewswire/ -- Zhendong Pharmaceutical announced that results from a multicenter, randomized, double-blind, placebo-controlled Phase IIb study evaluating its investigational Live Double Combined Lactobacillus Capsule for Vaginal Use for the treatmen...

2026-09-30 20:00 1608

EASD 2026 | Ecnoglutide Demonstrates Favorable Safety Profile in Adolescents with Obesity

HANGZHOU, China, Sept. 30, 2026 /PRNewswire/ -- At the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind") today announced that its Phase 1b randomized, double-blind, placebo-controlled study of ecnoglutide, the worl...

2026-09-30 19:00 3183

43% Improvement in Hair Breakage Resistance. Scalp Redness Down 14%. Singapore's CellResearch Presents Breakthrough Hair Data at AMWC Japan

Two independent laboratory studies on PTT-6®, the cord lining stem cell active from Singapore's CellResearch Corporation, deliver standards-based evidence on hair fiber strength and scalp condition — as the global hair and scalp care category climbs from USD 93.6 billion to USD 150.5 billion by 2...

2026-09-30 17:46 944
1 ... 14151617181920 ... 643